The global anthrax treatment market size was valued at USD 315.5 million in 2022. The market is projected to grow from USD 315.5 million in 2022 to USD 523.4 million by 2030, exhibiting a CAGR of 7.50% during the forecast period.
One of the main factors propelling the growth of the market for anthrax treatments is the rise in the number of anthrax victims worldwide. The threat of Bacillus anthracis exposure to civilian populations and military forces is growing, accelerating market growth. Researchers are receiving more funding to develop novel interventions, and this is also accelerating market growth. The rise in public-private partnerships and the expansion of research and development programs for facilitating creative advancements for innovative and efficient treatments are factors that also impact the market. The market for anthrax treatment is likely to develop. However, this is anticipated to be constrained by the high cost of the surgery and treatment as well as strict regulatory requirements for product approval.
Read Comprehensive Overview of Report @ https://marketsnresearch.com/report/1654/global-anthrax-treatment-market
LIST OF KEY COMPANIES PROFILED:
- Almirall, LLC
- Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
- Emergent
- Paratek Pharmaceuticals, Inc.
- Pfizer Inc.
- Bayer AG
- GSK plc
- Teva Pharmaceutical Industries Ltd.
- Lilly
Recent Development:
- In June 2022, it was announced by Emergent BioSolutions Inc. that the U.S. Food and Drug Administration (FDA) had accepted for review the Biologics License Application (BLA) for AV7909, a new anthrax vaccine candidate being tested for post-exposure disease prophylaxis following suspected or confirmed exposure to Bacillus anthracis in people aged 18 to 65 with suggested antibacterial drugs.
Read More News :
